---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003956"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:38:20.563045+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam appoints William H. Lewis as Chair of Board, succeeds founder Sander Slootweg

## Summary
- William H. Lewis, CEO of Insmed since 2012, appointed Chair of NewAmsterdam's Board effective Jan 4, 2024.
- He replaces Sander Slootweg (Forbion), Chairman since Company inception.
- Lewis receives annual cash retainer $40k + $30k Chair fee + $20k lead director fee; granted 100k share options.
- Board increased to ten; Lewis serves as temporary non-executive director until next shareholder meeting.
- Lewis appointed to Audit and Compensation Committees; meets Nasdaq independence standards.

## SEC filing metadata
- accession: 0001193125-24-003956
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/0001193125-24-003956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/d110563d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003956
- JSON: https://secwatch.observer/filing/0001193125-24-003956.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003956.txt

## Key facts
- Executive change
  Sander Slootweg departed as Chairman of the Board at NewAmsterdam Pharma Co N.V..
  - Action: succeeded
  - Role: Chairman of the Board
  source text: Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of the Board since inception.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/0001193125-24-003956-index.htm
- Executive change
  Willian H. Lewis was appointed as Chair of the Board at NewAmsterdam Pharma Co N.V..
  - Action: appointed
  - Role: Chair of the Board
  source text: appointed Willian H. Lewis, J.D., M.B.A., as Chair of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312524003956/0001193125-24-003956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.